Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CDK 9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian Cancer

9 Jul 2025

Abstract excerpt

Ovarian cancer patients with homologous recombination (HR) proficiency are more likely to develop resistance to poly (ADP-ribose) polymerase (PARP) inhibitors, resulting in poor prognosis. Harmine, a natural compound with verified clinical safety, is a potential inhibitor of HR activity. However, its effect on HR has not been tested in ovarian cancer. More importantly, its specific target involving the HR pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium signaling and nucleotide metabolism
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40629910
DOI: 10.1002/ptr.70021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CDK 9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian CancerPMID 40629910Read ↗

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.Semantic proximity Read ↗

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.Semantic proximity Read ↗

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read ↗

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerSemantic proximity Read ↗

Homologous recombination in cancer development, treatment and development of drug resistanceSemantic proximity Read ↗

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategiesSemantic proximity Read ↗

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity Read ↗

Directing the use of DDR kinase inhibitors in cancer treatment.Semantic proximity Read ↗

Exploiting the homologous recombination DNA repair network for targeted cancer therapySemantic proximity Read ↗

PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathwaySemantic proximity Read ↗

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.Semantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.